BriefIQ Markets · 8-K
Galera Therapeutics completes $350 million Series C Non-Voting Convertible Preferred Stock PIPE financing and enters merger agreement with Obsidian Therapeutics
Key Facts
- Galera completed the Concurrent PIPE Financing on July 31, 2026, selling Series C Preferred Stock for aggregate gross proceeds of approximately $350.0 million.
- The financing closing status was completed as of July 31, 2026.
Source
Filing details
- Form
- 8-K
- Symbol
- GRTX
- Company
- Galera Therapeutics, Inc.
- CIK
- 0001563577
- Accession number
- 0001193125-26-328716
- SEC filing date
- 2026-07-31
- SEC acceptance time
- 2026-07-31T20:31:37+00:00
- RSS publication time
- 2026-07-31T20:31:37+00:00
- BriefIQ published
- 2026-07-31T20:47:46.896229+00:00
- Reporting period
- 2026-07-31